Company intelligence / Profile preview

Mubadala Investment Company

Ownership: Private
Development stage: Other

Overview

Parent company manages a large global investment portfolio including ~45 life sciences firms with diverse clinical progressions. "Mubadala Bio" operates at commercial scale with over 10 facilities producing >2.5 billion tablets/capsules and >120 million injectables annually for more than 100 countries. No specific clinical trial results disclosed for proprietary drugs under "Mubadala Bio".

Therapeutic areas: Other
Modalities: Tablets/capsulesIVs/injectablesbroad biopharma manufacturinginvests in cell therapy and AI-driven drug discovery
Industry: Investors

Partnerships

Long-term collaborations with global industry leaders and academic institutions to accelerate innovation/manufacturing capacity in biopharma sector. Specific partners not named.

Beyond the preview

Go deeper on Mubadala Investment Company.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mubadala Investment Company.

Explore the full profile